Pfizer – PARP-inhibitor Combination Treatments in Prostate Cancer – RFP

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Geographic Scope: Global

Clinical Area:  Oncology – Genitourinary – Prostate

Link to full RFP: PARP-inhibitor Combination Treatments in Prostate Cancer

Application Due Date: April 24, 2023

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:

• Increasing the understanding of the mechanism of action, biological and clinical rationale for PARP-inhibitor combinations as potential treatments for prostate cancer.
• PARP-inhibitor combinations with androgen receptor targeted therapies.
• The evolving paradigm of the potential treatment of mCRPC with future PARP-inhibitor combinations.
• Optimal therapy management for PARP-inhibitor combinations in prostate cancer.